CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioInvent International AB

BIOI-B.ST
N/A

Next catalyst

Phase 2Q3 2027

BI-1910

Solid Tumors

Get an email about BIOI-B.ST's next catalysts

Track BioInvent International AB (BIOI-B.ST) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

Plus 1 more upcoming event in our data (Phase 2 readout).See the timeline

Catalyst Timeline

2 upcoming, 0 past

Phase 2Next

BI-1910 Phase 2 Est. Readout

Q3 2027~QBI-191035

Primary completion for BI-1910 trial (NCT06205706) in Solid Tumors

Source
Phase 2

BI-1206 Phase 2 Est. Readout

Q3 2027~QBI-1206140

Estimated primary completion for Acalabrutinib trial (NCT03571568) in Indolent B-Cell Non-Hodgkin Lymphoma. Topline data typically follows completion by weeks to months.

Source

Market Overview

Stock performance and key metrics

NASDAQBiotechnology🇸🇪Europe
Drug Pipeline

Frequently asked questions

What is in BioInvent International AB's drug pipeline?→

CatalystAlert tracks 15 drug candidates in BioInvent International AB's (BIOI-B.ST) pipeline across Phase 2. Its lead program is BI-1206 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is BioInvent International AB's next FDA catalyst?→

BioInvent International AB's (BIOI-B.ST) next tracked catalyst is a Phase 2 readout expected Q3 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track BIOI-B.ST biotech catalysts?→

Add BIOI-B.ST to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow BioInvent International AB's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply